shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
22 July 2020Big Pharma

Gilead continues oncology expansion with Tizona deal

Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.

The deal involves an initial $300 million investment, and an exclusive option for Gilead to buy the rest of the company for $1.25 billion.

Gilead can exercise this option following the publication of a Phase 1b study of Tizona’s investigational antibody, TTX-080, which Gilead called a “potential first-in-class” cancer medicine.

The US Food and Drug Administration has cleared Tizona’s investigational new drug application, and Tizona will begin a phase 1 clinical trial later this year.

“This agreement with Tizona adds to the significant progress we’ve made in the first half of this year in building out a strong and diverse immuno-oncology pipeline,” said Gilead CEO Daniel O’Day, adding: “We now have multiple opportunities to develop novel therapies that will improve the treatment of cancer.”

“Gilead’s support will enable Tizona to accelerate and broaden our TTX-080 clinical program while also enabling us to rapidly advance our rich, first-in-class preclinical portfolio and target validation efforts,” said Tizona CEO Scott Clarke.

Earlier this year, Gilead announced a deal to buy immuno-oncology company  Forty Seven, including its lead product candidate magrolimab.

The deals mark a broadening of Gilead’s portfolio, which has traditionally been based on antivirals for diseases like HIV, Ebola, and most recently, COVID-19.

Its strength in the antiviral market for these diseases has occasionally drawn criticism over the price of its flagship drugs, particularly in the case of HIV and pre-exposure prophylaxis.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.
Generics
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

More on this story

Americas
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.
Generics
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

More on this story

Americas
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.
Generics
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.